Diana Canals Hernaez
Associate Scientist Zymeworks
Seminars
Thursday 29th January 2026
Advancing ZW209 Trispecific Design with In Vitro & In Vivo Models to Improve DLL3-Directed Responses
10:00 am
- Incorporating CD28 co-stimulation with DLL3 and CD3 engagement to enhance T cell activation, proliferation, and sustained cytotoxicity beyond bispecific benchmarks
- Demonstrating superior in vitro and in vivo anti-tumor activity through serial challenge assays and xenograft models that highlight efficacy and T cell fitness
- Establishing translational confidence with PK, cytokine release, and safety profiling in primates to support clinical development of ZW209 in DLL3-positive cancers
